300108 *ST吉药控股
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)39.587342.907158.994230.187-186.180
总资产报酬率 ROA (%)-7.442-16.890-11.886-17.512-12.724
投入资产回报率 ROIC (%)-11.160-22.841-16.822-25.020-16.377

边际利润分析
销售毛利率 (%)32.28130.23826.90424.92021.549
营业利润率 (%)-98.438-100.198-49.147-56.806-56.838
息税前利润/营业总收入 (%)-53.236-82.127-14.136-43.230-41.740
净利润/营业总收入 (%)-108.336-128.835-58.641-68.828-64.465

收益指标分析
经营活动净收益/利润总额(%)64.86164.036108.67755.33063.610
价值变动净收益/利润总额(%)-0.023-4.057-56.914-0.074-0.072
营业外收支净额/利润总额(%)6.77421.60813.92816.11010.824

偿债能力分析
流动比率 (X)0.1770.2210.2800.3050.443
速动比率 (X)0.1340.1600.1810.2030.300
资产负债率 (%)154.624142.174116.476118.66699.007
带息债务/全部投入资本 (%)123.958109.96190.592122.58295.784
股东权益/带息债务 (%)-29.629-19.0324.945-22.1651.604
股东权益/负债合计 (%)-14.985-10.3152.972-14.7831.160
利息保障倍数 (X)-1.017-1.797-0.329-1.766-1.898

营运能力分析
应收账款周转天数 (天)138.017158.645145.310153.392257.386
存货周转天数 (天)159.502228.669205.138178.190205.180